Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Lilly Seeks EUA For COVID-19 Antibody, Unveils Positive Combo Data

Oct 07 2020

• By Joseph Haas

Corona patient — Lilly is seeking an FDA emergency use authorization for LY-CoV555

Related Content

Lilly Claims Proof Of Concept For Neutralizing Antibodies In COVID-19 Therapy

Sep 16 2020

Coronavirus Update: Moderna And Pfizer Respond To Vaccine Trial Transparency Demands

Sep 18 2020

Regeneron’s COVID-19 Antibody Cocktail Shows Early Promise, But Does It Merit An EUA?

Sep 30 2020

Regeneron and Roche Await Data On Potential COVID-19 Blockbuster

Sep 03 2020

Executive Privilege: How Giving Trump Special Access To Experimental COVID Treatment Could Backfire

Oct 05 2020

Gilead Sets Remdesivir Price, Commits Nearly All Near-Term Supplies To US

Jun 30 2020

Coronavirus Update: Cheaper Remdesivir Available In India

Aug 13 2020

Related Companies

Gilead Sciences, Inc.

Eli Lilly and Company

Regeneron Pharmaceuticals, Inc.

Roche Holding AG

Additional Topics

Coronavirus COVID-19 Clinical Trials Drug Approval Standards Business Strategies Infectious Diseases BioPharmaceutical

More from COVID-19

More from Scrip

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.